原文 |
译文 |
Clin Exp Rheumatol. 2011 Jan 19. Intentional etanercept use during pregnancy for maintenance of remission in rheumatoid arthritis.Scioscia C, Scioscia M, Anelli MG, Praino E, Bettocchi S, Lapadula G. Rheumatology Unit, Department of Internal Medicine and Public Health, University of Bari, Bari, Italy. ezio.scioscia@hotmail.com. AbstractOBJECTIVES: Rheumatoid arthritis is associated with an increased risk of adverse pregnancy outcomes. TNF inhibitors are effective in the treatment of signs and symptoms of the disease although their safety during pregnancy is debated. METHODS: Two cases of women with rheumatoid arthritis in complete remission of the disease with etanercept who decided to continue the therapy throughout their pregnancy are presented. A longitudinal evaluation of the disease activity showed a satisfactory control and good pregnancy outcomes were obtained. A flare of the disease after delivery was not observed. CONCLUSIONS: Etanercept seems to be safe during pregnancy and lactation. A good control of the activity of the disease was reported throughout the pregnancy and during puerperium, when a reactivation of rheumatoid arthritis is often observed.
|
RA患者妊娠期使用依那西普维持缓解 Scioscia C,et al.Clin Exp Rheumatol. 2011 Jan 19. 目的:RA与妊娠不良结局风险增高有关。TNF抑制剂能有效改善RA的体征和症状,但其妊娠期安全性有所争议。 方法:2例RA女性患者使用依那西普后达到完全缓解,她们决定在妊娠期继续治疗。纵向评估疾病活动度显示,病情得到有效控制,而且妊娠结局良好。分娩后疾病无复发。 结论:依那西普在妊娠期和哺乳期安全性好。妊娠期和产褥期疾病活动度控制良好,而这期间常可观察到RA复发。 |